Who are ACE inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vasotec, angiotensin blockade, Matching placebo to Ramipril, Enalapril/hydrochlorothiazide, Captopril Tablets, ACEI/DIU.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ace-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

ACE inhibitor — Competitive Intelligence Brief

ACE inhibitor (ACE inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACE inhibitor (ACE inhibitor) — University of Cambridge. ACE inhibitors block the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II and thereby reducing vasoconstriction and aldosterone release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACE inhibitor TARGET	ACE inhibitor	University of Cambridge	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
angiotensin blockade	angiotensin blockade	The University of Hong Kong	marketed	Angiotensin receptor blocker (ARB) or ACE inhibitor	Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE)
Matching placebo to Ramipril	Matching placebo to Ramipril	Novartis	marketed	Placebo (matching formulation for ACE inhibitor)
Enalapril/hydrochlorothiazide	Enalapril/hydrochlorothiazide	Erasmus Medical Center	marketed	ACE inhibitor / thiazide diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter
Captopril Tablets	Captopril Tablets	Ain Shams University	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
ACEI/DIU	ACEI/DIU	Shanghai Jiao Tong University School of Medicine	marketed	ACE inhibitor/Diuretic combination	Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
Bioprojet · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
Children's Hospital of Fudan University · 1 drug in this class
Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Ethicare GmbH · 1 drug in this class
Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACE inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/ace-inhibitor. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab